Finding and working with a prescriber

Every non-prescriber in UK aesthetics runs their business on a relationship the industry barely discusses in public. Botulinum toxin is a prescription-only medicine. So are hyaluronidase, the enzyme you reach for when a filler treatment goes wrong, and the adrenaline in a proper anaphylaxis kit. If you cannot prescribe, someone else must, and every UK regulator now requires that person to sit in a room with your patient before any prescription exists. The GDC said so in 2013, the GMC in 2016, the GPhC strengthened its guidance in February 2025, and the NMC made its position explicit from 1 June 2025, extending the face-to-face requirement to follow-up appointments and emergency kits. Remote sign-off is dead everywhere.

So “who is your prescriber?” is not a paperwork question. The answer decides which patients you can treat, on which days, at what margin, and whether your insurance is worth the PDF it arrived as. Yet almost nobody publishes a practical guide to finding a prescriber, agreeing terms and spotting the arrangements that end careers. Here is ours.

What the rules require

A prescriber (a doctor, a dentist, or a nurse or pharmacist holding an independent prescribing qualification) must consult face to face with the named patient before prescribing a prescription-only medicine for a cosmetic procedure. Not a video call, not a WhatsApp photo, not a signature on a stack of forms. The prescription belongs to that patient, for that treatment plan, and the prescriber remains accountable for the prescribing decision even though you administer the treatment.

If your training glossed over this, you are not alone. It is one of the most common gaps we see in delegates arriving from other providers, and it is the first thing an insurer checks when a claim lands. Our guide to becoming an aesthetic practitioner covers where prescribing sits in the wider career map; this guide is about making the arrangement work day to day.

The three working models

Model	How it works	The honest downside
The prescriber attends your clinic	You book patients into blocks. The prescriber consults each one face to face and issues prescriptions, and you treat, usually at a follow-on appointment once the product is dispensed.	You are paying for someone’s travel and time, so blocks need to be full to make financial sense. Hard in your first year.
You take patients to the prescriber	Patients attend the prescriber’s own clinic or a shared premises for consultation, then you treat separately.	Two appointments per treatment. Some patients will not bother, and your conversion rate pays for it.
You work inside a prescriber-led clinic	You are employed, or on a room or percentage arrangement, in a clinic where a prescriber is present as part of normal operations.	Less autonomy and a revenue share, in exchange for supervision, mentoring and a prescribing problem that is already solved.

For a first-year injector the third model is underrated. The revenue share stings, but you inherit working systems and someone senior down the corridor the first time a patient presents with blanching skin. Independence is far more enjoyable once your complication management is fluent rather than theoretical.

What prescribers charge

The norm is a per-patient consultation fee, usually payable whether or not the patient goes ahead. Rates vary with geography, volume and how much the prescriber actually does beyond signing; some run the consultation as genuine assessment and informal mentoring, others do the minimum their regulator requires. Figures commonly quoted publicly run from around £20 to £50 per patient, with day rates for block sessions negotiated separately.

Worked example, assumptions stated. Suppose your three-area toxin price is £200, product and consumables cost £45, and the prescriber charges £30 per patient. Your gross margin is £125 per treatment before room hire, insurance and your time, roughly 63% of the ticket. The same treatment with no prescriber fee margins at about 78%. That gap, repeated across every toxin patient you ever see, is the true cost of not being a prescriber, and it is why the V300 conversation eventually happens in every nurse injector’s career.

Red flags worth walking away from

• Anyone offering remote, phone, video or email sign-off. Every UK regulator has banned it for cosmetic injectables. A prescriber willing to break that rule for your convenience will not stand behind you when something goes wrong.
• Prescriptions in bulk, or toxin supplied ahead of named patients. Stock sitting in your fridge with nobody’s name attached is a regulatory finding waiting to be written up.
• A prescriber who never actually sees the patient. If the arrangement on paper says face to face but the diary says otherwise, the paper will not save either of you.
• A clinic or training provider that says “we’ll sort the prescribing” without a named person whose registration you can check. Vague reassurance is not an arrangement.
• A prescriber who declines to confirm the arrangement in writing, or to be named on your insurance proposal. Both are thirty-second tasks for anyone operating properly.

Who carries which liability

The split is cleaner than most people assume. The prescriber owns the prescribing decision: patient assessment, suitability, drug choice and dose rationale. You own the treatment: technique, procedure-specific consent, aftercare and recognising and responding to complications. A claim can attach to either side or both, which is why both parties need insurance that reflects what each actually does. Your policy should record that you work with a named prescriber under a face-to-face model. The prescriber’s policy needs to cover prescribing for cosmetic use, which some NHS-focused arrangements do not. Our insurance and prescribing guide takes the cover question apart in detail.

The emergency kit problem

Hyaluronidase and adrenaline are prescription-only medicines too, and this is where arrangements most often fail quietly. The NMC’s June 2025 position explicitly includes emergency supplies, and the practical logic is brutal: there is no lawful way to conjure a prescription in the middle of a vascular occlusion. The plan must exist before you treat your first patient. Agree in writing what emergency medicines you hold, on what basis, how they are replenished after use or expiry, and what the escalation call looks like at 7pm on a Saturday. If a prospective prescriber has no ready answer here, they have thought about your fee and not your patients. This is also why our foundation course runs a complications drill rather than a complications lecture.

V150 is not enough

Nurses sometimes arrive holding a V150, the community practitioner prescribing qualification, assuming it solves everything. It does not. The V150 permits prescribing from a limited community formulary and is not adequate for aesthetics toxin work. The qualification that changes your position is the V300, nurse and midwife independent prescribing, which allows you to prescribe within your competence, including botulinum toxin, hyaluronidase and your own emergency kit. If you are a nurse mapping this route, start with our injectable training for nurses page.

Becoming a prescriber yourself

The V300 is a university course, typically around six months part time, with fees commonly £2,000–£3,000 per public university and provider pages. The hard part is rarely the study. It is the Designated Prescribing Practitioner, the experienced prescriber who must supervise your practice hours. Nurses employed in the NHS usually find a DPP inside their own team; nurses who have already left for aesthetics often cannot. “I can’t find a DPP because I don’t have an NHS team anymore” is one of the most common things we hear, and the honest answers are unglamorous. Negotiate DPP support into the contract with the prescriber you already pay. Ask your university, since some maintain DPP networks. Or, if you are still employed, complete the V300 before you resign rather than after.

Pharmacists are the quiet story here. Pharmacist independent prescribers already work in aesthetics, and from 2026 newly qualified pharmacists register with a prescribing annotation from day one, which will steadily increase the supply of prescribers in the market. If that is you, see injectable training for pharmacists.

Due diligence before agreeing terms

1. Check the prescriber’s name and registration on the GMC, GDC, NMC or GPhC register, with prescriber status visible.
2. Confirm the face-to-face consultation model in writing, follow-ups included.
3. Agree the per-patient fee, any block rates, and what happens when a patient consults but does not proceed.
4. Put the emergency medicines plan in place before your first patient, hyaluronidase and adrenaline included.
5. Cover availability: holidays, sickness, and the notice period for ending the arrangement.
6. Confirm their insurance covers prescribing for cosmetic use, and that yours records the arrangement.
7. Agree where consultation records live and how both of you access them if a complaint arrives.
8. Test the complications escalation route once, before you ever need it.

Where this fits your plan

We are a training academy, not a prescriber-matching service, and we will not pretend a prescriber arrives stapled to your certificate. What we do instead: teach the arrangement properly, with the liability split and emergency-kit planning in the curriculum rather than an afterthought, run monthly case-review calls where alumni bring exactly these situations, and offer a free eligibility review if you are weighing the V300 against staying a non-prescriber. If you want the map before the detail, start with the route finder.

This guide is editorial information, not legal or clinical advice. Regulatory positions and figures checked 11 July 2026.